AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00487617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fruit juice or placebo absorption
Description: absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
Study NCT00487617 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice or placebo absorption
Description: absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
Study NCT03113643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy
Study NCT03113643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401
Description: SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
Study NCT03113643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
Study NCT04367584 — intervention group
Intervention type: OTHER
Intervention: Clinical and laboratory examination
Description: Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
Study NCT03628287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revised Care Coordination Program
Description: Greater focusing, tailoring and cues for delivery of key components of Care Coordination
Study NCT03628287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Original Care Coordination Program
Description: Original Care Coordination
Study NCT01275313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lightweight wheelchair
Description: Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
Study NCT01275313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Protection Cushion
Description: Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
Study NCT04085328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID015385 soft contact lenses
Description: Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
Study NCT04085328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A soft contact lenses
Description: Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
Study NCT01371513 — intervention group
Intervention type: OTHER
Intervention: continuous screening
Description: practice patterns for screening prostate cancer
Study NCT03362151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular pasta
Description: Regular pasta (Approximately 42 grams carbohydrate per meal)
Study NCT03362151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein pasta
Description: High protein pasta (Approximately 38 grams carbohydrate per meal)
Study NCT03362151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice
Description: White rice (Approximately 43 grams carbohydrate per meal)
Study NCT04447274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
Study NCT01801696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage tx group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study NCT03018405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose.
Study NCT04508439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
Study NCT04508439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
Study NCT01801696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage wait-list control group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study NCT03821168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of bevacizumab and erythropoietin
Description: injection of bevacizumab and erythropoietin
Study NCT03821168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of bevacizumab
Description: under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
Study NCT02195986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Cream, 0.01%
Description: Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
Study NCT02195986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® 0.01% cream
Description: Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
Study NCT02195986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Cream
Description: Placebo Vaginal Cream ( 1 x 2 g for 7 days)
Study NCT02802800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Plyometric exercises
Study NCT01786928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
Study NCT01346748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Description: Sinvastatin 80 mg per day - 21 days versus placebo
Study NCT00771810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Once daily subcutaneous injection of 100 ug/kg
Study NCT00771810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Once daily subcutaneous injection of 300 ug/kg
Study NCT00771810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily subcutaneous injection of placebo
Study NCT00449176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER
Description: 50, 100, 150, 200, 250 mg twice daily for 15 weeks
Study NCT00449176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone CR
Description: 10, 20, 30, 40, 50 mg twice daily for 15 weeks
Study NCT00449176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice daily for 15 weeks
Study NCT00623090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational internet site on prostate cancer screening
Description: Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
Study NCT00623090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational print booklet
Description: Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
Study NCT00623090 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
Study NCT01900782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: Prefilled syringe.
Study NCT01900782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B
Description: Prefilled syringe.
Study NCT01900782 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prefilled syringe to match experimental drug and active comparator.
Study NCT04357262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: StreaMD
Description: Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
Study NCT01926756 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Straight catheterization
Description: Patient will receive the current standard practice of straight catheterization intraoperatively.
Study NCT01926756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No straight catheterization
Description: Patients will not be catheterized which is an experimental change from the current practice at our hospital.
Study NCT02920827 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
Study NCT02920827 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Placebo vaginal ring containing no dapivirine
Study NCT00837174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat in combination with Bortezomib
Description: Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
Study NCT03130751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pocket Coach for AYA with Cancer
Description: The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
Study NCT02085148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
Study NCT02085148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine (Cellcristin®)
Description: Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
Study NCT02085148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Irinotecan Cell pharm®)
Description: Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
Study NCT02302443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose
Study NCT02302443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: Single dose subcutaneous administration of active comparator
Study NCT03392714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-B(O)AD
Description: rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sniffin' Sticks Odor Identification and Hedonic Scale
Description: This task measures odor identification accuracy and perceived pleasantness of odors.
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks Odor Identification and Hedonic Scale
Description: This task measures odor identification accuracy and perceived pleasantness of odors.
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose Taste Preference Assessment
Description: This task measures participant ratings of sucrose preference.
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sucrose Taste Preference Assessment
Description: This task measures participant ratings of sucrose preference.
Study NCT03396718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation radio(chemo)therapy - Level 1
Description: 54/ 59,4 Gy
Study NCT03396718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation radio(chemo)therapy - Level 2
Description: 48,8/ 55 Gy
Study NCT03396718 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radio(chemotherapy)
Description: 60/ 66 Gy
Study NCT01350063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)
Description: One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
Study NCT01350063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water storage container (Jerry can)
Description: Shallow tubewell water should be stored in 10L container.
Study NCT01350063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT02598102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac for pain relief
Study NCT02598102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison
Study NCT04316858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate
Description: 90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
Study NCT04316858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
Study NCT04316858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zero calorie carbonated drink
Description: 800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
Study NCT03548714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Intervention 1 includes PT150 with alcohol consumption
Study NCT03548714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage
Description: Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
Study NCT02833402 — intervention group
Intervention type: DEVICE
Intervention: InterStim Therapy
Description: Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
Study NCT02688608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV once every 3 weeks
Study NCT01629875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic equivalent of Clostridium Botulinum A Toxin
Study NCT01629875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (Clostridium Botulinum A Toxin)
Study NCT01250158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver-PILP kit
Description: Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen.
Study NCT02669680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
Study NCT02669680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Study NCT02669680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Study NCT03075137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External counter pulsation (ECP)
Description: standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
Study NCT01713712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
Study NCT00738556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stents (Cypher and Taxus)
Description: Spot or full length stenting of a coronary lesion
Study NCT01697007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA vaccine
Study NCT01697007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zetajet
Study NCT01697007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax Electroporation
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Preferences Task
Description: Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Preferences Task
Description: Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Ratio (PR) Task
Description: In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
Study NCT03575273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio (PR) Task
Description: In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
Study NCT03575273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Electrophysiology
Description: To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.